Seguridad y eficacia de erenumab en pacientes con migraña sin aura
Revista Original

Palabras clave

Migraña; Aura; Péptido relacionado con el gen de la calcitonina


Conociendo la importancia de los péptidos relacionados con el gen de la calcitonina (CGRP), surgen nuevas dianas terapéuticas para el tratamiento de mantenimiento de la migraña, tanto con cómo sin aura.


Knowing the importance of calcitonin gene-related peptides (CGRP), new therapeutic targets are emerging for the maintenance treatment of migraine both with and without aura.


  • Recibido: 01 Junio 2022
  • Revisión: 13 Junio 2022
  • Aceptado: 04 Julio 2022
Revista Original


Vol 78 Nº 9, págs. 913-928. 2018. Maasumi K, Michael RL, Rapoport AM. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine. Springer Link.

Vol 13. 2020. Andreou AP, Fuccaro M, Lambru G. The role of erenumab in the treatment of migraine. Therapeutic Advances in Neurological Disorders. Doi:

Vol 392 Nº 10161, págs. 2280-2287. 2018. Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomized, double-blind, placebo-controlled, phase 3b study. Lancet. Doi:

Vol 61 Nº 6, págs. 927-935. 2021. Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Headache. Doi:

Vol 95 Nº 5, págs. 469-479. 2020. Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Wright IK, Chou DE, Klatt J, Picard H, Lenz RA, Mikol DD. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology. Doi: